Andy Schmeltz, Global President of Pfizer Oncology, presented at the Cowen and Company Health Care Conference on March 14, 2018. The presentation discussed Pfizer's growing oncology portfolio, fueled by drugs like IBRANCE and XTANDI, with potential for multiple new drug approvals and indications in the coming years. It noted forward-looking statements are subject to risks and uncertainties. The presentation also provided an overview of Pfizer's rich oncology pipeline including drugs and indications in various phases of clinical trials. Key focus areas for Pfizer Oncology include generating evidence for broader use of drugs like talazoparib and avelumab, identifying combination therapies, innovative patient engagement, and advancing access